Adherence Tradeoff to Multiple Preventive Therapies and All-Cause Mortality After Acute Myocardial Infarction.

[1]  W. Cefalu,et al.  Standards of Medical Care in Diabetes—2018 Abridged for Primary Care Providers , 2018, Clinical Diabetes.

[2]  M. Wiese,et al.  Clinical Outcomes Associated with Medication Regimen Complexity in Older People: A Systematic Review , 2017, Journal of the American Geriatrics Society.

[3]  Sei J. Lee,et al.  Association of &bgr;-Blockers With Functional Outcomes, Death, and Rehospitalization in Older Nursing Home Residents After Acute Myocardial Infarction , 2017, JAMA internal medicine.

[4]  Andrea Cherrington,et al.  Standards of Medical Care in Diabetes—2017 Abridged for Primary Care Providers , 2017, Clinical Diabetes.

[5]  V. Fuster,et al.  Assessing the Impact of Medication Adherence on Long-Term Cardiovascular Outcomes. , 2016, Journal of the American College of Cardiology.

[6]  V. Fuster,et al.  Early Intravenous Beta-Blockers in Patients With ST-Segment Elevation Myocardial Infarction Before Primary Percutaneous Coronary Intervention. , 2016, Journal of the American College of Cardiology.

[7]  J. Robinson,et al.  Association Between Preadmission Functional Status and Use and Effectiveness of Secondary Prevention Medications in Elderly Survivors of Acute Myocardial Infarction , 2016, Journal of the American Geriatrics Society.

[8]  Manfred S. Green,et al.  Effect of adherence to evidence‐based therapy after acute myocardial infarction on all‐cause mortality , 2015, Pharmacoepidemiology and drug safety.

[9]  T. Henry,et al.  Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study. , 2015, American heart journal.

[10]  C. Charlesworth,et al.  Polypharmacy Among Adults Aged 65 Years and Older in the United States: 1988-2010. , 2015, The journals of gerontology. Series A, Biological sciences and medical sciences.

[11]  M. Brookhart,et al.  Using claims data to predict dependency in activities of daily living as a proxy for frailty , 2015, Pharmacoepidemiology and drug safety.

[12]  M. Goldstein,et al.  Health Outcomes Associated with Polypharmacy in Community‐Dwelling Older Adults: A Systematic Review , 2014, Journal of the American Geriatrics Society.

[13]  R. Huupponen,et al.  Lifestyle factors as predictors of nonadherence to statin therapy among patients with and without cardiovascular comorbidities , 2014, Canadian Medical Association Journal.

[14]  Jackson T. Wright,et al.  2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). , 2014, JAMA.

[15]  Hassan Khan,et al.  Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. , 2013, European heart journal.

[16]  Jane A. Linderbaum,et al.  2013 ACCF/AHA Guideline for the Management of ST‐Elevation Myocardial Infarction: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[17]  Jane A. Linderbaum,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[18]  Deepak L. Bhatt,et al.  β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. , 2012, JAMA.

[19]  R. Califf,et al.  2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2011, Circulation.

[20]  Sebastian Schneeweiss,et al.  The implications of therapeutic complexity on adherence to cardiovascular medications. , 2011, Archives of internal medicine.

[21]  N. Danchin,et al.  Evidence-based pharmacotherapy after myocardial infarction in France: adherence-associated factors and relationship with 30-month mortality and rehospitalization. , 2010, Archives of cardiovascular diseases.

[22]  W. Winkelmayer,et al.  Trends in adherence to secondary prevention medications in elderly post‐myocardial infarction patients , 2008, Pharmacoepidemiology and drug safety.

[23]  Gissi-Hf Investigators.  Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[24]  R Peto,et al.  Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. , 2008, Lancet.

[25]  Xu Zhang,et al.  A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model , 2007, Comput. Methods Programs Biomed..

[26]  S. Bangalore,et al.  A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. , 2007, The American journal of cardiology.

[27]  W. Elliott,et al.  Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis , 2007, The Lancet.

[28]  D. Alter,et al.  Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. , 2007, JAMA.

[29]  Harlan M Krumholz,et al.  Impact of medication therapy discontinuation on mortality after myocardial infarction. , 2006, Archives of internal medicine.

[30]  L. Køber,et al.  Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. , 2006, European heart journal.

[31]  A. Cohen-Solal,et al.  Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). , 2005, European heart journal.

[32]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[33]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[34]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[35]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[36]  T. Brennan,et al.  Untangling the relationship between medication adherence and post-myocardial infarction outcomes: medication adherence and clinical outcomes. , 2014, American heart journal.

[37]  M. Seguí Díaz,et al.  [Effect of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus. A meta-analysis]. , 2014, Semergen.

[38]  M. Clearfield.  Rosuvastatin in older patients with systolic heart failure. , 2009, Current atherosclerosis reports.

[39]  L. Tavazzi,et al.  Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. , 2008, Lancet.

[40]  R. Eckel,et al.  Mellitus: A Scientific Statement From the American Heart Association and the Primary Prevention of Cardiovascular Diseases in People With Diabetes , 2007 .

[41]  H. Bøtker,et al.  Is an additional post-myocardial infarction beta-blocker trial required in the era of early revascularization? , 2004, European heart journal.

[42]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[43]  P. Rucci,et al.  Pharmacoepidemiology and Prescription , 2022 .